Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

GLP overexpression is associated with poor prognosis in Chronic Lymphocytic Leukemia and its inhibition induces leukemic cell death.

Alves-Silva JC, de Carvalho JL, Rabello DA, Serejo TRT, Rego EM, Neves FAR, Lucena-Araujo AR, Pittella-Silva F, Saldanha-Araujo F.

Invest New Drugs. 2018 May 31. doi: 10.1007/s10637-018-0613-x. [Epub ahead of print]

PMID:
29855824
2.

Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms.

Machado-Neto JA, Fenerich BA, Scopim-Ribeiro R, Eide CA, Coelho-Silva JL, Dechandt CRP, Fernandes JC, Rodrigues Alves APN, Scheucher PS, Simões BP, Alberici LC, de Figueiredo Pontes LL, Tognon CE, Druker BJ, Rego EM, Traina F.

Cell Death Dis. 2018 Feb 22;9(3):311. doi: 10.1038/s41419-017-0256-4.

3.

Impact of the ICAL on the treatment of acute leukemia.

Rego EM.

Blood Adv. 2017 Mar 14;1(8):516. doi: 10.1182/bloodadvances.2017002147. eCollection 2017 Mar 14. No abstract available.

4.

Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia.

Lucena-Araujo AR, Pereira-Martins DA, Koury LC, Franca-Neto PL, Coelho-Silva JL, de Deus Wagatsuma VM, Melo RAM, Bittencourt R, Pagnano K, Pasquini R, Chiattone CS, Fagundes EM, Chauffaille ML, Schrier SL, Tallman MS, Ribeiro RC, Grimwade D, Ganser A, Löwenberg B, Lo-Coco F, Sanz MA, Berliner N, Rego EM.

Blood Adv. 2017 Sep 15;1(21):1807-1814. doi: 10.1182/bloodadvances.2017005926. eCollection 2017 Sep 26.

5.

Acute myeloid leukemia with e1a2 BCR-ABL1 fusion gene: two cases with peculiar molecular and clinical presentations.

da Silva FB, Machado-Neto JA, Koury LCA, Bertini VHLL, Ratis CA, Chauffaille MLLF, Velloso EDRP, Simões BP, Rego EM, Traina F.

Rev Bras Hematol Hemoter. 2017 Oct - Dec;39(4):379-384. doi: 10.1016/j.bjhh.2017.07.001. Epub 2017 Aug 3. No abstract available.

6.

Reactive oxygen species production triggers green tea-induced anti-leukaemic effects on acute promyelocytic leukaemia model.

Torello CO, Shiraishi RN, Della Via FI, Castro TCL, Longhini AL, Santos I, Bombeiro AL, Silva CLA, Queiroz MLS, Rego EM, Saad STO.

Cancer Lett. 2018 Feb 1;414:116-126. doi: 10.1016/j.canlet.2017.11.006. Epub 2017 Nov 10.

PMID:
29129782
7.

Paclitaxel induces Stathmin 1 phosphorylation, microtubule stability and apoptosis in acute lymphoblastic leukemia cells.

Machado-Neto JA, Rodrigues Alves APN, Fernandes JC, Coelho-Silva JL, Scopim-Ribeiro R, Fenerich BA, da Silva FB, Scheucher PS, Simões BP, Rego EM, Traina F.

Heliyon. 2017 Sep 28;3(9):e00405. doi: 10.1016/j.heliyon.2017.e00405. eCollection 2017 Sep.

8.

Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.

Iaccarino L, Ottone T, Hasan SK, Divona M, Cicconi L, Lavorgna S, Alfonso V, Basso G, Barragán E, Bocchia M, Rego EM, Grimwade D, Voso MT, Lo-Coco F.

Leuk Lymphoma. 2018 May;59(5):1268-1270. doi: 10.1080/10428194.2017.1369067. Epub 2017 Aug 24. No abstract available.

PMID:
28838264
9.

Comparison of microRNA expression in high-count monoclonal B-cell lymphocytosis and Binet A chronic lymphocytic leukemia.

Furtado FM, Scheucher PS, Santana BA, Zanette DL, Calado RDT, Rego EM, Matos DM, Falcão RP.

Rev Bras Hematol Hemoter. 2017 Jul - Sep;39(3):237-243. doi: 10.1016/j.bjhh.2017.03.006. Epub 2017 Apr 22.

10.

Evaluation of the European LeukemiaNet recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low- and middle-income countries (LMIC): A Brazilian experience.

Benicio MTL, Ribeiro AFT, Américo AD, Furtado FM, Glória AB, Lima AS, Santos SM, Xavier SG, Lucena-Araujo AR, Fagundes EM, Rego EM.

Leuk Res. 2017 Sep;60:109-114. doi: 10.1016/j.leukres.2017.07.005. Epub 2017 Jul 24.

PMID:
28777950
11.

Treating acute promyelocytic leukaemia in Latin America: lessons from the International Consortium on Acute Leukaemia experience.

Corrêa de Araujo Koury L, Ganser A, Berliner N, Rego EM.

Br J Haematol. 2017 Jun;177(6):979-983. doi: 10.1111/bjh.14589. Epub 2017 May 3. Review.

PMID:
28466545
12.

Telomere length analysis in monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Binet A.

Furtado FM, Scheucher PS, Santana BA, Scatena NF, Calado RT, Rego EM, Matos DM, Falcão RP.

Braz J Med Biol Res. 2017 Apr 13;50(5):e6019. doi: 10.1590/1414-431X20176019.

13.

Biological X-ray irradiator characterization for use with small animals and cells.

Bruno AC, Mazaro SJ, Amaral LL, Rego EM, Oliveira HF, Pavoni JF.

Braz J Med Biol Res. 2017 Mar 2;50(3):e5848. doi: 10.1590/1414-431X20165848.

14.

Molecular and hematologic relapses in adult patients with acute promyelocytic leukemia: a cohort study.

Azevedo IF, Magalhães MG, Souto FR, Neves WB, Melo FC, Rego EM, Melo RA.

Rev Bras Hematol Hemoter. 2017 Jan - Mar;39(1):46-51. doi: 10.1016/j.bjhh.2016.09.010. Epub 2016 Oct 21.

15.

35 years of the Brazilian Journal of Medical and Biological Research.

Rego EM, Pereira Leite J, Bensenor I, Chammas R, Nogueira de Francischi J, da Luz PL.

Braz J Med Biol Res. 2017 Feb 6;50(1):e6153. doi: 10.1590/1414-431X20166153.

16.

ΔNp73 overexpression promotes resistance to apoptosis but does not cooperate with PML/RARA in the induction of an APL-leukemic phenotype.

Lucena-Araujo AR, Coelho-Silva JL, Pereira-Martins DA, Thomé C, Scheucher PS, Lange AP, Paiva HH, Hemmelgarn BT, Morais-Sobral MC, Azevedo EA, Franca-Neto PL, Franca RF, Silva CL, Krause A, Rego EM.

Oncotarget. 2017 Jan 31;8(5):8475-8483. doi: 10.18632/oncotarget.14295.

17.

The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia.

Lange AP, Lima AS, Lucena-Araujo AR, Jácomo RH, Melo RA, Bittencourt RI, Pasquini R, Pagnano K, Fagundes EM, Chauffaille ML, Chiattone CS, Sanz MA, Lo-Coco F, Grimwade D, Rego EM.

Br J Haematol. 2018 Mar;180(6):915-918. doi: 10.1111/bjh.14490. Epub 2016 Dec 26. No abstract available.

PMID:
28025822
18.

IRS1/β-Catenin Axis Is Activated and Induces MYC Expression in Acute Lymphoblastic Leukemia Cells.

Fernandes JC, Rodrigues Alves APN, Machado-Neto JA, Scopim-Ribeiro R, Fenerich BA, da Silva FB, Simões BP, Rego EM, Traina F.

J Cell Biochem. 2017 Jul;118(7):1774-1781. doi: 10.1002/jcb.25845. Epub 2017 Mar 15.

PMID:
27987331
19.

Association between the TP53 Arg72Pro polymorphism and clinical outcomes in acute myeloid leukemia.

Bezerra MF, Coelho-Silva JL, Nascimento JC, Benicio MT, Rocha CR, Machado CG, Rego EM, Bezerra MA, Lucena-Araujo AR, Beltrão EI.

Haematologica. 2017 Feb;102(2):e43-e46. doi: 10.3324/haematol.2016.155069. Epub 2016 Oct 20. No abstract available.

20.

Single-nucleotide polymorphism array (SNP-A) improves the identification of chromosomal abnormalities by metaphase cytogenetics in myelodysplastic syndrome.

da Silva FB, Machado-Neto JA, Bertini VHLL, Velloso EDRP, Ratis CA, Calado RT, Simões BP, Rego EM, Traina F.

J Clin Pathol. 2017 May;70(5):435-442. doi: 10.1136/jclinpath-2016-204023. Epub 2016 Nov 11.

PMID:
27836923
21.

Reversine triggers mitotic catastrophe and apoptosis in K562 cells.

Rodrigues Alves AP, Machado-Neto JA, Scheucher PS, Paiva HH, Simões BP, Rego EM, Traina F.

Leuk Res. 2016 Sep;48:26-31. doi: 10.1016/j.leukres.2016.06.011. Epub 2016 Jul 1.

PMID:
27447890
22.

Guidelines on the treatment of acute myeloid leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: Project guidelines: Associação Médica Brasileira - 2015.

Bittencourt R, Bortolheiro TC, de Lourdes Lopes Ferrari Chauffaille M, Fagundes EM, Pagnano KB, Rego EM, Bernardo WM.

Rev Bras Hematol Hemoter. 2016 Jan-Feb;38(1):58-74. doi: 10.1016/j.bjhh.2016.01.001. Epub 2016 Feb 5. No abstract available.

23.

Post-Sepsis State Induces Tumor-Associated Macrophage Accumulation through CXCR4/CXCL12 and Favors Tumor Progression in Mice.

Mota JM, Leite CA, Souza LE, Melo PH, Nascimento DC, de-Deus-Wagatsuma VM, Temporal J, Figueiredo F, Noushmehr H, Alves-Filho JC, Cunha FQ, Rego EM.

Cancer Immunol Res. 2016 Apr;4(4):312-22. doi: 10.1158/2326-6066.CIR-15-0170. Epub 2016 Jan 27.

24.

Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia.

Oliveira-Santos W, Rabello DA, Lucena-Araujo AR, de Oliveira FM, Rego EM, Pittella Silva F, Saldanha-Araujo F.

Tumour Biol. 2016 Jul;37(7):9473-81. doi: 10.1007/s13277-016-4846-z. Epub 2016 Jan 20.

PMID:
26790435
25.

High ΔNp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia.

Lucena-Araujo AR, Kim HT, Thomé C, Jacomo RH, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Glória AB, Chauffaille Mde L, Athayde M, Chiattone CS, Mito I, Bendlin R, Souza C, Bortolheiro C, Coelho-Silva JL, Schrier SL, Tallman MS, Grimwade D, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Sanz MA, Rego EM.

Blood. 2015 Nov 12;126(20):2302-6. doi: 10.1182/blood-2015-01-623330. Epub 2015 Oct 1.

26.

Potential roles of microRNA-29a in the molecular pathophysiology of T-cell acute lymphoblastic leukemia.

Oliveira LH, Schiavinato JL, Fráguas MS, Lucena-Araujo AR, Haddad R, Araújo AG, Dalmazzo LF, Rego EM, Covas DT, Zago MA, Panepucci RA.

Cancer Sci. 2015 Oct;106(10):1264-77. doi: 10.1111/cas.12766. Epub 2015 Sep 21.

27.

FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.

Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C; FLORENCE Study Group.

Ann Oncol. 2015 Oct;26(10):2155-61. doi: 10.1093/annonc/mdv317. Epub 2015 Jul 27.

PMID:
26216382
28.

Halofuginone inhibits phosphorylation of SMAD-2 reducing angiogenesis and leukemia burden in an acute promyelocytic leukemia mouse model.

Assis PA, De Figueiredo-Pontes LL, Lima AS, Leão V, Cândido LA, Pintão CT, Garcia AB, Saggioro FP, Panepucci RA, Chahud F, Nagler A, Falcão RP, Rego EM.

J Exp Clin Cancer Res. 2015 Jun 23;34:65. doi: 10.1186/s13046-015-0181-2.

29.

All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.

Sanz MA, Montesinos P, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte MR, Martínez L, Jacomo RH, Gutiérrez-Aguirre H, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Vellenga E, Holowiecka A, González-Huerta AJ, Fernández P, De la Serna J, Brunet S, De Lisa E, González-Campos J, Ribera JM, Krsnik I, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Rego EM; IC-APL and PETHEMA and HOVON Groups.

Ann Hematol. 2015 Aug;94(8):1347-56. doi: 10.1007/s00277-015-2393-0. Epub 2015 May 15.

PMID:
25975975
30.

Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer.

Wei S, Kozono S, Kats L, Nechama M, Li W, Guarnerio J, Luo M, You MH, Yao Y, Kondo A, Hu H, Bozkurt G, Moerke NJ, Cao S, Reschke M, Chen CH, Rego EM, Lo-Coco F, Cantley LC, Lee TH, Wu H, Zhang Y, Pandolfi PP, Zhou XZ, Lu KP.

Nat Med. 2015 May;21(5):457-66. doi: 10.1038/nm.3839. Epub 2015 Apr 13.

31.

Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia.

Rabello Ddo A, Lucena-Araujo AR, Alves-Silva JC, da Eira VB, de Vasconcellos MC, de Oliveira FM, Rego EM, Saldanha-Araujo F, Pittella Silva F.

Blood Cells Mol Dis. 2015 Jan;54(1):97-102. doi: 10.1016/j.bcmd.2014.07.013. Epub 2014 Aug 15.

PMID:
25131810
32.

Guidelines on the diagnosis and treatment for acute promyelocytic leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Médica Brasileira - 2013.

Pagnano KB, Rego EM, Rohr S, de Lourdes Chauffaille M, Jacomo RH, Bittencourt R, Firmato AB, Fagundes EM, Moraes Melo RA, Bernardo W.

Rev Bras Hematol Hemoter. 2014 Jan-Feb;36(1):71-89. doi: 10.5581/1516-8484.20140018. Epub 2014 Mar 12. Portuguese. No abstract available.

33.

Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.

Lucena-Araujo AR, Kim HT, Jacomo RH, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Chauffaille Mde L, Chiattone CS, Lima AS, Ruiz-Argüelles G, Undurraga MS, Martinez L, Kwaan HC, Gallagher R, Niemeyer CM, Schrier SL, Tallman MS, Grimwade D, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Sanz MA, Rego EM.

Ann Hematol. 2014 Dec;93(12):2001-10. doi: 10.1007/s00277-014-2142-9. Epub 2014 Jul 2.

PMID:
24981688
34.

Prognostic impact of KMT2E transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study.

Lucena-Araujo AR, Kim HT, Jacomo RH, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, de Lourdes Chauffaille M, Chiattone CS, Lima AS, Kwaan HC, Gallagher R, Niemeyer CM, Schrier SL, Tallman MS, Grimwade D, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Sanz MA, Rego EM.

Br J Haematol. 2014 Aug;166(4):540-9. doi: 10.1111/bjh.12921. Epub 2014 May 3.

PMID:
24796963
35.

Guidelines on the diagnosis and treatment for acute promyelocytic leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Médica Brasileira - 2013.

Pagnano KB, Rego EM, Rohr S, Chauffaille Mde L, Jacomo RH, Bittencourt R, Firmato AB, Fagundes EM, Melo RA, Bernardo W.

Rev Bras Hematol Hemoter. 2014;36(1):71-92. doi: 10.5581/1516-8484.20140018. No abstract available.

36.

Synthetic phosphoethanolamine has in vitro and in vivo anti-leukemia effects.

Ferreira AK, Santana-Lemos BA, Rego EM, Filho OM, Chierice GO, Maria DA.

Br J Cancer. 2013 Nov 26;109(11):2819-28. doi: 10.1038/bjc.2013.510. Epub 2013 Nov 7.

38.

Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia.

Gimenes-Teixeira HL, Lucena-Araujo AR, Dos Santos GA, Zanette DL, Scheucher PS, Oliveira LC, Dalmazzo LF, Silva-Júnior WA, Falcão RP, Rego EM.

Exp Hematol Oncol. 2013 Apr 8;2(1):10. doi: 10.1186/2162-3619-2-10.

39.

Genetic mutations in patients with acute myeloid leukemia and leukostasis.

De Santis GC, Benicio MT, Oliveira LC, Falcão RP, Rego EM.

Acta Haematol. 2013;130(2):95-7. doi: 10.1159/000346442. Epub 2013 Mar 23. No abstract available.

PMID:
23548579
40.

Inhibition of NF- κ B by Dehydroxymethylepoxyquinomicin Suppresses Invasion and Synergistically Potentiates Temozolomide and γ -Radiation Cytotoxicity in Glioblastoma Cells.

Brassesco MS, Roberto GM, Morales AG, Oliveira JC, Delsin LE, Pezuk JA, Valera ET, Carlotti CG Jr, Rego EM, de Oliveira HF, Scrideli CA, Umezawa K, Tone LG.

Chemother Res Pract. 2013;2013:593020. doi: 10.1155/2013/593020. Epub 2013 Feb 21.

41.

FISH analysis for TET2 deletion in a cohort of 362 Brazilian myeloid malignancies: correlation with karyotype abnormalities.

de Oliveira FM, Miguel CE, Lucena-Araujo AR, de Lima AS, Falcão RP, Rego EM.

Med Oncol. 2013 Mar;30(1):483. doi: 10.1007/s12032-013-0483-1. Epub 2013 Feb 7.

PMID:
23389918
42.

Disrupting membrane raft domains by alkylphospholipids.

Gomide AB, Thomé CH, dos Santos GA, Ferreira GA, Faça VM, Rego EM, Greene LJ, Stabeli RG, Ciancaglini P, Itri R.

Biochim Biophys Acta. 2013 May;1828(5):1384-9. doi: 10.1016/j.bbamem.2013.01.017. Epub 2013 Feb 1.

43.

Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL.

Rego EM, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte Mdel R, Jacomo RH, Gutiérrez-Aguirre H, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Chauffaille Mde L, Chiattone CS, Martinez L, Meillón LA, Gómez-Almaguer D, Kwaan HC, Garcés-Eisele J, Gallagher R, Niemeyer CM, Schrier SL, Tallman M, Grimwade D, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Sanz MA.

Blood. 2013 Mar 14;121(11):1935-43. doi: 10.1182/blood-2012-08-449918. Epub 2013 Jan 14.

44.

Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome: correlation with G-banding analysis and FISH.

Oliveira FM, Lucena-Araujo AR, Favarin Mdo C, Palma PV, Rego EM, Falcão RP, Covas DT, Fontes AM.

Exp Hematol. 2013 Feb;41(2):198-208. doi: 10.1016/j.exphem.2012.10.009. Epub 2012 Oct 22.

PMID:
23092930
45.

Molecular basis for the diagnosis and treatment of acute promyelocytic leukemia.

Bassi SC, Rego EM.

Rev Bras Hematol Hemoter. 2012;34(2):134-9. doi: 10.5581/1516-8484.20120033.

46.

Linker for activation of T-cell family member2 (LAT2) a lipid raft adaptor protein for AKT signaling, is an early mediator of alkylphospholipid anti-leukemic activity.

Thomé CH, dos Santos GA, Ferreira GA, Scheucher PS, Izumi C, Leopoldino AM, Simão AM, Ciancaglini P, de Oliveira KT, Chin A, Hanash SM, Falcão RP, Rego EM, Greene LJ, Faça VM.

Mol Cell Proteomics. 2012 Dec;11(12):1898-912. doi: 10.1074/mcp.M112.019661. Epub 2012 Sep 22.

47.

Immediate effects of bilateral grade III mobilization of the talocrural joint on the balance of elderly women.

Pertille A, Macedo AB, Dibai Filho AV, Rêgo EM, Arrais LD, Negri JR, Teodori RM.

J Manipulative Physiol Ther. 2012 Sep;35(7):549-55. doi: 10.1016/j.jmpt.2012.06.004. Epub 2012 Aug 16.

PMID:
22902138
48.

Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma.

Maiolino A, Hungria VT, Garnica M, Oliveira-Duarte G, Oliveira LC, Mercante DR, Miranda EC, Quero AA, Peres AL, Barros JC, Tanaka P, Magalhães RP, Rego EM, Lorand-Metze I, Lima CS, Renault IZ, Braggio E, Chiattone C, Nucci M, de Souza CA; Brazilian Multiple Myeloma Study Group (BMMSG/GEMOH).

Am J Hematol. 2012 Oct;87(10):948-52. doi: 10.1002/ajh.23274. Epub 2012 Jun 23.

49.

Comparative analysis of the pathological events involved in immune and non-immune TRALI models.

Tamarozzi MB, Soares SG, Sá-Nunes A, Paiva HH, Saggioro FP, Garcia AB, Lucena-Araujo AR, Falcão RP, Bordin JO, Rego EM.

Vox Sang. 2012 Nov;103(4):309-21. doi: 10.1111/j.1423-0410.2012.01613.x. Epub 2012 May 25.

PMID:
22624696
50.

Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups.

Gadji M, Adebayo Awe J, Rodrigues P, Kumar R, Houston DS, Klewes L, Dièye TN, Rego EM, Passetto RF, de Oliveira FM, Mai S.

Clin Cancer Res. 2012 Jun 15;18(12):3293-304. doi: 10.1158/1078-0432.CCR-12-0087. Epub 2012 Apr 26.

Supplemental Content

Support Center